Radioimmunotherapy of Non-Hodgkin’s Lymphoma: From the ‘Magic Bullets’ to ‘Radioactive Magic Bullets’
نویسندگان
چکیده
Radioimmunotherapy (RIT) of lymphoma with Zevalin and Bexxar was approved by FDA in 2002 and 2003, respectively, for the treatment of relapsed or refractory CD20+ follicular B-cell non-Hodgkin´s lymphoma. In 2009, Zevalin was also approved for consolidation therapy in patients with follicular non-Hodgkin's lymphoma that achieve a partial or complete response to first-line chemotherapy. For follicular lymphoma patients, the overall response and progression-free survival rates have significantly improved since the implementation of RIT. The predominant complication of RIT is hematological toxicity that is usually manageable. There are ongoing trials to further define the expanding role of RIT as first line or concomitant therapy in the treatment of lymphoma as well as for certain antibiotic resistant infections and aggressive malignancies. There is also growing interest in the development of newer protocols for increased and more uniform dose delivery resulting in better outcomes and improved patient survival. This review will primarily focus on the role of RIT in treatment of non-Hodgkin's lymphoma, which is of established clinical utility and FDA approved. The mechanism of RIT, available radionuclides and pharmacokinetics, therapy administration, clinical utility and toxicities, and future directions would be discussed.
منابع مشابه
Radioimmunotherapy of hematological cancer: problems and progress.
Introduction The optimistic and naive view of the early l980s that mAbs2 were ‘ ‘ magic bullets’ ‘ has now been replaced by a more realistic understanding of the many obstacles to their effective use. Although some mAbs have produced significant antitumor responses in humans (1-6), a number of factors, including the weak cytotoxic activity of many murine mAbs. the difficulty in delivering mAbs ...
متن کاملImmunoconjugates : " Magic Bullets " for Cancer Therapy ?
Conjugating cytotoxic agents to antibodies allows for site-specific delivery of the agent to tumor cells and should provide increased efficacy and reduced non-specific toxicity. These site-specific cpotogc agents are known as irnmunoconjugates or "magic bullets" and have demonstrated great promise as therapeutic agents for cancer and other diseases. The historical developments and future potent...
متن کاملPutting the magic in magic bullets: top three global priorities for sexually transmitted infection control
INTRODUCTION Setting practical priorities for sexually transmitted infection (STI) control is a balance between idealism and pragmatism. Infections transmitted through unsafe sex (chlamydia, gonorrhoea, syphilis, HIV, hepatitis B and human papillomavirus (HPV) infections) rank in the top five causes of the global burden of disease. Their distribution in populations is driven by a complex mixtur...
متن کاملAntibodies – The “Magic Bullets” for Drug Delivery?
Abbreviations: Ab/Abs: Antibody/Antibodies; CD19: Cluster of Differentiation antigen associated with B-lymphocyte Antigen; CD4: Cluster of Differentiation glycoprotein on the surface of e.g., helper T cells; DNA: Deoxyribonucleic Acid; EGF/r3: Anti-epidermal growth factor receptor; Fc: “Fragment crystallizable” of the Ab molecule; FcRn: The neonatal Fc receptor; IgG1: Immunoglobulin G1; mAb: Mo...
متن کامل